Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Fundam Clin Pharmacol ; 32(1): 60-68, 2018 Feb.
Article in English | MEDLINE | ID: mdl-28853229

ABSTRACT

The use of ketamine (Ket) as a pharmacological model of schizophrenia is an important tool for understanding the main mechanisms of glutamatergic regulated neural oscillations. Thus, the aim of the current study was to evaluate Ket-induced changes in the average spectral power using the hippocampal quantitative electroencephalography (QEEG). To this end, male Wistar rats were submitted to a stereotactic surgery for the implantation of an electrode in the right hippocampus. After three days, the animals were divided into four groups that were treated for 10 consecutive days with Ket (10, 50, or 100 mg/kg). Brainwaves were captured on the 1st or 10th day, respectively, to acute or repeated treatments. The administration of Ket (10, 50, or 100 mg/kg), compared with controls, induced changes in the hippocampal average spectral power of delta, theta, alpha, gamma low or high waves, after acute or repeated treatments. Therefore, based on the alterations in the average spectral power of hippocampal waves induced by Ket, our findings might provide a basis for the use of hippocampal QEEG in animal models of schizophrenia.


Subject(s)
Brain Waves , Electrocardiography , Hippocampus/physiopathology , Ketamine , Schizophrenia/diagnosis , Animals , Behavior, Animal , Disease Models, Animal , Male , Predictive Value of Tests , Rats, Wistar , Schizophrenia/chemically induced , Schizophrenia/physiopathology , Schizophrenic Psychology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...